Kendra Sweeney - Evelo Biosciences Head Markets
| EVLODelisted Stock | USD 8.23 2.68 24.56% |
Insider
Kendra Sweeney is Head Markets of Evelo Biosciences
| Phone | 617 577 0300 |
| Web | https://www.evelobio.com |
Evelo Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.8325) % which means that it has lost $0.8325 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (62.3276) %, meaning that it created substantial loss on money invested by shareholders. Evelo Biosciences' management efficiency ratios could be used to measure how well Evelo Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Evelo Biosciences currently holds 51.14 M in liabilities with Debt to Equity (D/E) ratio of 1.55, which is about average as compared to similar companies. Evelo Biosciences has a current ratio of 4.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Evelo Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Evelo Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evelo Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evelo to invest in growth at high rates of return. When we think about Evelo Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| AO FRACP | Assembly Biosciences | 65 | |
| MBA MD | Generation Bio Co | 55 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| PharmD Bigora | Processa Pharmaceuticals | 64 | |
| Matthew Stanton | Generation Bio Co | 51 | |
| MD MBA | Generation Bio Co | 46 | |
| Stephanie Yao | Kronos Bio | N/A | |
| Geoffrey Birkett | Ensysce Biosciences | 61 | |
| Lauren White | C4 Therapeutics | N/A | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Stacy Markel | Nuvation Bio | 59 | |
| ChiHsin King | ABVC Biopharma | 76 | |
| BCh BM | Kronos Bio | 40 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Uri MD | Assembly Biosciences | 52 | |
| CPA MS | Erasca Inc | 55 | |
| Diane Esq | Windtree Therapeutics | 55 | |
| Jonathan MD | Erasca Inc | 52 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Daniel Welch | Nuvation Bio | 63 | |
Management Performance
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 |
Evelo Biosciences Leadership Team
Elected by the shareholders, the Evelo Biosciences' board of directors comprises two types of representatives: Evelo Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evelo. The board's role is to monitor Evelo Biosciences' management team and ensure that shareholders' interests are well served. Evelo Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evelo Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Carriere, VP Officer | ||
| Mark Bodmer, Chief Scientific Officer and Presidentident of Research and Development | ||
| Jonathan Zung, Chief Officer | ||
| Leslie WardwellScott, VP Integration | ||
| Chun Zhang, Chief Officer | ||
| Julie Carretero, Chief Officer | ||
| Jessica Cotrone, VP Communications | ||
| Balkrishan Gill, CEO Pres | ||
| Kendra Sweeney, Head Markets | ||
| Marella Thorell, CFO Treasurer |
Evelo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Evelo Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -62.33 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 23.69 M | ||||
| Shares Outstanding | 18.93 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 83.13 % | ||||
| Number Of Shares Shorted | 430.1 K | ||||
| Price To Earning | (4.19) X | ||||
| Price To Book | 3.51 X | ||||
| EBITDA | (108.41 M) |
Pair Trading with Evelo Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evelo Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evelo Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Evelo Pink Sheet
Moving against Evelo Pink Sheet
| 0.72 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.6 | DTIL | Precision BioSciences | PairCorr |
| 0.53 | VERU | Veru Inc Fiscal Year End 13th of December 2024 | PairCorr |
| 0.47 | DOMH | Dominari Holdings | PairCorr |
| 0.46 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Evelo Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evelo Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evelo Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evelo Biosciences to buy it.
The correlation of Evelo Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evelo Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evelo Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evelo Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Evelo Pink Sheet
If you are still planning to invest in Evelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evelo Biosciences' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |